@article{TCR12678,
author = {Maitri Kalra and Harikrishna Nakshatri},
title = {Will PI3K-targeted therapies for cancer become a reality?},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 2},
year = {2017},
keywords = {},
abstract = {In a recent issue of Annals of Oncology, Vuylsteke and colleagues presented the interim analysis of phase II PEGGY study on the use of pictilisib [a pan-phosphoinositide-3-kinase (PI3K) inhibitor] plus paclitaxel in hormone receptor positive human epidermal receptor 2 (HER2) negative (ER+/HER2−) locally advanced or metastatic breast cancer (1). This clinical trial is one among the many clinical clinicals to report clinical benefits and toxicity associated with PI3K-targeted therapies.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/12678}
}